Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

73%

8 of 11 completed trials have results

Key Signals

8 with results

Enrollment Performance

Analytics

N/A

7(87.5%)

Phase 2

1(12.5%)

8Total

N/A(7)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT01525862Not ApplicableCompleted

XprESS Maxillary Balloon Dilation Study

Role: lead

NCT01115309Not ApplicableCompleted

XprESS Registry Study

Role: lead

NCT00986830Not ApplicableCompleted

Healthcare Utilization and Outcomes of FinESS Treatment in the Office

Role: lead

NCT01612780Not ApplicableCompleted

Trans-Nasal Maxillary Multi-Sinus Balloon Dilation Study

Role: lead

NCT04136977Completed

XprESS ET Registry

Role: lead

NCT02391584Not ApplicableCompleted

XprESS Eustachian Tube Dilation Study

Role: lead

NCT02278484Not ApplicableCompleted

Sinus Balloon Dilation in Pediatric Patients

Role: lead

NCT01525849Not ApplicableCompleted

Randomized Evaluation of Maxillary Antrostomy Versus Ostial Dilation Efficacy Through Long-Term Follow-Up

Role: lead

NCT00645762Phase 2Completed

Balloon REmodeling Antrostomy THErapy Study

Role: lead

NCT00849953Completed

FinESS Registry Study

Role: lead

NCT01319305Completed

BREATHE Long-Term Follow-Up Study

Role: lead

All 11 trials loaded